Functions of p53 protein include induction of G1 arrest of the cell cycle and apoptosis after DNA damage. 3, 4) Mutations of the p53 gene reported thus far seem to cluster predominantly around five highly conserved amino acid domains which are coded for by exons 5 to 8. 5, 6) Numerous studies have been conducted on mutation analysis of the p53 gene in rodents with chemically induced tumors. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] These analyses revealed that the frequency of p53 alterations in rodent experimental tumors varied greatly depending on the chemical agents and tumor types.
Analysis of p53 mutations in experimental tumors may offer interesting and important information to elucidate the mechanism of mutagenesis and the biological significance of the mutation in carcinogenesis. We established a series of methylcholanthrene (MCA)-induced sarcomas in C57BL/6N×C3H/HeN F 1 (BCF 1 ) mice. 19) MCA is a welldefined carcinogen that binds to the Ah receptor and activates cytochrome P450. 20, 21) In this study, we analyzed the spectrum of p53 gene mutations in MCA-induced mouse sarcomas. In contrast to the results of earlier studies, the present analysis revealed that p53 gene mutation is quite common in MCA-induced mouse sarcomas.
MATERIALS AND METHODS
Sarcoma induction MCA-induced sarcomas analyzed in this study were described previously. 19) Briefly, BCF 1 or C3H/HeN×C57BL/6N (CBF 1 ) mice were injected subcutaneously at several regions on the back with 0.5-1 mg of MCA dissolved in olive oil. When tumors had grown to 1 cm in diameter, they were excised and examined histologically. Sixty-three independent tumors were obtained, of which five were from CBF 1 mice (tumors numbered CB), and 26 from BCF 1 mice (tumors numbered BC). A portion of each tumor was minced with scissors and transferred to a 3-cm culture dish. The samples were grown for 10 days in order to minimize contamination with stromal cells. All of the tumors of the present study were transplantable to syngeneic mice. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis DNA was isolated according to the procedure described previously. 19, 22) Oligonucleotide primers for exons 5 to 8 of the p53 tumor suppressor gene were synthesized. 23) The sequences are shown in Table I . All primers included a portion of intron in order to avoid amplification of the p53 pseudogene. PCR-SSCP analysis was done according to the standard procedure. 24) Briefly, primers were end-labeled with [γ-32 P] ATP using T4 polynucleotide kinase. Genomic DNA was amplified for 30 cycles in 10 µl of a reaction mixture containing 100 ng of template DNA, 4 µM end-labeled primers, 200 µM each of dNTPs (dATP, dCTP, dGTP, dTTP) and 0.05 units of Taq DNA polymerase. Each cycle consisted of 94°C for 1 min, 52°C for 1 min and 72°C for 30 s. Reaction mixtures were treated with 10 µl of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol, then denatured at 90°C for 2 min. An aliquot (1 µl/lane) was applied to a 6% nondenaturing polyacrylamide gel containing 5% glycerol, and electrophoresed at 30-40 Watts for 2-3 h at room temperature with fan cooling. The gel was dried and exposed to X-ray film. Direct sequencing of p53 mutations Putative mutant bands of the p53 gene detected by PCR-SSCP analysis were eluted from the dried gel and used for re-amplifica- tion. PCR-amplified products were cycle-sequenced by the dye terminator method (373 DNA Sequencer, Applied Biosystems; Dye Terminator Cycle Sequence FS Reaction Kit, Perkin-Elmer Cetus, Norwalk, CT). Primers for DNA sequencing were the same as those for PCR-SSCP. Loss of heterozygosity (LOH) analysis of chromosome 11 Allelic losses of chromosome 11 in tumor DNAs were analyzed using the five polymorphic markers along the chromosome. The primers for PCR and the size difference of the two alleles are shown in Table II . 25) 
RESULTS
Spectrum of p53 mutations Genomic DNAs from 63 MCA-induced mouse sarcomas were examined by PCR-SSCP analysis of exons 5 to 8 of the p53 gene (Fig. 1) . PCR products showing mobility shifts on SSCP gel were eluted and subjected to direct sequencing (Fig. 2) . The results are summarized in Table III . In total, 45 out of 63 sarcomas carried mutation of the p53 gene. Among these, 53 mutations were identified. Missense mutations were the most prevalent and 49 of the 53 were of this type. The rest included two cases of nonsense mutations, one silent mutation and one insertion. Mutations were found frequently at codons 172, 242, 245, 246 and 270, and these codons correspond to the hot spots of mutation in the human p53 gene. Five of these 7 cases involved different exons. It is likely that these mutations occurred on different alleles of the gene. In two cases (case 41 and 53), double mutations were located in consecutive codons of the same exon, which suggests that these mutations were on the same allele. The spectrum of p53 mutations is summarized in Table IV . The most prevalent type was G:C→T:A transversion (25 cases, 47%). Distribution of the 53 mutations in MCA-induced mouse sarcomas is shown in Fig. 3 , where the amino acid sequence of the mouse protein is aligned with that of human p53 protein. Some of the hot spots of p53 gene 25) Sarcomas were examined for LOH using polymorphic markers of chromosome 11 (Table II) . Fig. 4 illustrates representative cases of such analysis with D11Mit320, which is located near the p53 gene (within 1 cM). Only 10 among 45 sarcomas (22%) showed LOH at this locus. Except for one case (case 48), all other markers examined were also lost, which suggests the involvement of a large region. Nine of 10 sarcomas with LOH were accompanied with single p53 mutation, which indicated mutation of one allele and loss of the other allele. Interestingly, nine of the 10 losses involved the C57BL allele in BC sarcomas.
DISCUSSION
Point mutations of the p53 gene were frequent in MCA-induced mouse sarcomas, as previously reported by Halevy et al. 26) They identified seven p53 mutations, of which four were G:C→T:A transversion. In this study, we examined mutation in the p53 gene in 63 MCA-induced mouse sarcomas, and we detected 53 mutations in 45 out of 63 sarcomas. This frequency is one of the highest among chemically induced rodent tumors so far examined. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In addition, our study of MCA-induced sarcomas revealed some similarities in the distribution of p53 gene mutation between human and mouse. Mutations were observed at mouse codons 172 (6 cases), 242 (2 cases), 245 (2 cases), 246 (3 cases), 270 (4 cases) and 279 (1 case), and these corresponded to human p53 gene hot spots 175, 245, 248, 249, 273 and 282. In addition, mutations were frequently detected at codons 241 (7 cases), and 278 (2 cases). In the case of human cancers, about half of the G-to-A transitions were at the CpG site. 27) Eight of 13 cases of G:C→A:T transition in the present study were at the CpG site of codon 172 (6 cases), 245 (1 case), or 270 (1 case). All of these cases correspond to CpG site hot spots of human cancers.
MCA belongs to the family of polycyclic aromatic hydrocarbons and is a well-known carcinogen to rodents. Polycyclic aromatic hydrocarbons are metabolically activated and the metabolites bind to the 2-amino group of guanine in DNA to produce bulky carcinogen-DNA adducts which produce predominantly the G:C→T:A transversions. 28) We previously examined K-ras mutations in MCAinduced mouse sarcomas (H. Watanabe et al., unpublished data). Interestingly, the spectrum of K-ras mutations was similar to that of p53, and G:C→T:A transversion predominated (50%). Thus, the spectrum of mutation by MCA seems to be similar for both the K-ras gene and the p53 gene. A large variety of mutations has been identified in the p53 gene in human cancers. 29 The high frequency of p53 mutations in MCA-induced mouse sarcomas offers a unique opportunity to elucidate the role of p53 gene mutation in the etiology of carcinogenesis. Analysis of human bone and soft tissue sarcomas identified 42 somatic alterations of the p53 gene, of which 21 were point mutations. 30) The spectrum of these point mutations was different from that of our MCA-induced mouse sarcomas.
p53 gene knock-out mice develop sarcomas and lymphomas. 31) Analysis of mutations of the wild-type allele in sarcomas arising in p53 heterozygous mice by Southern analysis revealed loss of the wild-type allele in the majority of cases. 32) Human colorectal cancers were shown to suffer frequent LOH of the p53 gene, 33) while such LOH was rare in chemically induced mouse colon tumors. 13) Rodent tumor models have been examined thoroughly for LOH of chromosome 11. 15, [34] [35] [36] We have examined LOH on chromosome 11, where the p53 tumor suppressor gene is located. We detected 10 cases of LOH (22%) of chromosome 11 among 45 sarcomas with p53 mutations. Nine of these 10 cases were accompanied with single p53 mutation. A case of double mutations occurred at consecutive codons, 152 and 153 (case 41), and this case also carried LOH of chromosome 11. Multiple mutations of one allele and LOH of another allele are consistent with the two-hit theory. However, cases with LOH and mutation, and cases with mutations on both alleles were rather infrequent, and the two-hit mechanism may not be applicable to the majority of cases. Therefore, most MCAinduced sarcomas may be due to the dominant negative p53 gene mutation mechanism. 37) Our present analysis revealed the preferential loss of regions of mouse chromosome 11 derived from C57BL/ 6N in MCA-induced sarcomas of BCF 1 mice. It is not known whether the preference has bias toward maternal origin, or whether there is a strain difference of the allele. Preferential LOH of the maternally derived alleles was reported in several human tumors for WT1, IGF2 and KIP2. [38] [39] [40] Strain preference in LOH has been noted in some mouse tumors. 41, 42) Analysis of a larger number of CBF 1 tumors should clarify the mechanism of the allelic preference of LOH of chromosome 11 in MCA-induced mouse sarcomas.
